Get the Stockscreener App
5.43
0.18%
0.010
Third Harmonic Bio Inc stock is traded at $5.43, with a volume of 37,814.
It is up +0.18% in the last 24 hours and up +3.43% over the past month.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
See More
Previous Close:
$5.42
Open:
$5.44
24h Volume:
37,814
Relative Volume:
0.07
Market Cap:
$239.18M
Revenue:
-
Net Income/Loss:
$-32.74M
P/E Ratio:
-6.622
EPS:
-0.82
Net Cash Flow:
$-24.89M
1W Performance:
-0.37%
1M Performance:
+3.43%
6M Performance:
-50.77%
1Y Performance:
-54.56%
1-Day Range:
$5.43
$5.4467
1-Week Range:
$5.40
$5.47
52-Week Range:
$3.18
$16.02
Third Harmonic Bio Inc Stock (THRD) Company Profile
Name
Third Harmonic Bio Inc
Sector
Industry
Phone
(209) 727-2457
Address
1700 MONTGOMERY STREET, SAN FRANCISCO
Compare THRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
5.43 | 239.18M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-11-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-09-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-07-24 | Initiated | Raymond James | Outperform |
| Dec-16-22 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-22 | Initiated | Cowen | Outperform |
| Oct-10-22 | Initiated | Jefferies | Buy |
| Oct-10-22 | Initiated | Morgan Stanley | Overweight |
View All
Third Harmonic Bio Inc Stock (THRD) Latest News
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - BioPharma Dive
Third Harmonic Bio stockholders approve liquidation plan, set distribution By Investing.com - Investing.com India
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
THRD Stockholders Approve Liquidation Plan with Initial Payouts Expected | THRD Stock News - GuruFocus
Third Harmonic Bio receives stockholder approval of plan of liquidation - TipRanks
Third Harmonic Bio reports updated THB335 data, initiates THB335 sale - TipRanks
ADC Therapeutics reveals layoffs, $100M PIPE; Third Harmonic seeks buyer for asset - Endpoints News
Third Harmonic Bio To Dissolve; THB335 Shows Promise, Sale Process Now Underway - Nasdaq
Third Harmonic Bio stockholders approve liquidation plan, set distribution - Investing.com
Third Harmonic Bio Approves Liquidation and Dissolution Plan - TipRanks
THRD Advances THB335 to Phase 2 Trials with Positive Phase 1 Results | THRD Stock News - GuruFocus
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335 - The Manila Times
Third Harmonic Bio Shareholders Win Big: $5.35/Share Payout Approved as Drug Shows 85% Efficacy - Stock Titan
Third Harmonic Bio Approves Key Proposals at Annual Meeting - TipRanks
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
Fierce Biotech Layoff Tracker 2025: Rapt reduces workforce; Plexium pares down staff - Fierce Biotech
Third Harmonic Bio Reports Q1 2025 Financial Results - TipRanks
Cancer drugmaker iTeos to shut down - BioPharma Dive
It’s been three months without a biotech IPO - Endpoints News
THIRD HARMONIC BIO Earnings Results: $THRD Reports Quarterly Earnings - Nasdaq
Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Third Harmonic Bio Announces Plan of Liquidation and Dissolution - ADVFN
Here’s Why Third Harmonic Bio (THRD) Fell in Q1 - Insider Monkey
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down - MSN
Third Harmonic Bio CSO steps down, enters separation agreement - Investing.com Australia
Third Harmonic Bio Plans Liquidation With Lucrative Payouts - Finimize
Third Harmonic Bio CSO steps down, enters separation agreement By Investing.com - Investing.com South Africa
Dupixent bounces back in treating hives with FDA approval - BioWorld MedTech
New fund Alis offers struggling biotechs an off-ramp: Finance Report - BioCentury
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
SF biotech company, once worth nearly $1 billion, plans to shut down - SFGATE
Biotech Alert: Searches spiking for these stocks today - TipRanks
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Third Harmonic Bio (THRD) Seeks Stockholder Approval for Liquida - GuruFocus
Third Harmonic Bio plans to liquidate the company, sell urticaria treatment - MSN
Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties - TipRanks
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered - MSN
$26bn Brighton Jones hires new CFO - Citywire
Third Harmonic Bio plans liquidation and asset sale By Investing.com - Investing.com South Africa
Third Harmonic Bio Inc Stock (THRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Third Harmonic Bio Inc Stock (THRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
| BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):